Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 5/20 | 0.34 |
| ▸ | CA2 | P00918 | 5/20 | 0.34 |
| ▸ | CA12 | O43570 | 3/20 | 0.34 |
| ▸ | CA9 | Q16790 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
| ▸ | ACACA | Q13085 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9324298 | 0.86 | ACLY (0.39) | CYP4F2CYP4A11ALDH1A1ACLYACACB | |
| SCHEMBL9322440 | 0.83 | ACLY (0.43) | CYP4F2CYP4A11ACLYACACBACACA | |
| SCHEMBL29135457 | 0.83 | — | — | |
| SCHEMBL9785092 | 0.79 | FDPS (0.33) | CA1CA2CA12CA9LMNA | |
| SCHEMBL9099589 | 0.75 | CES2 (0.42) | TSHR | |
| SCHEMBL5076633 | 0.75 | CES2 (0.42) | TSHR | |
| SCHEMBL5075315 | 0.74 | ACLY (0.56) | CYP4F2CYP4A11SMN1; SMN2TSHRACLY | |
| SCHEMBL28809593 | 0.74 | CYP4F2 (0.41) | CYP4F2CYP4A11SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL11108272 | 0.72 | — | — | |
| SCHEMBL9837397 | 0.72 | ACLY (0.54) | CYP4F2CYP4A11SMN1; SMN2TSHRACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10307434-B2 | Nucleic acid prodrugs and methods of use thereof | WAVE LIFE SCIENCES LTD. (SG) | 2019-06-04 | — | — | US | disclosed |
| US-9744183-B2 | Nucleic acid prodrugs and methods of use thereof | WAVE LIFE SCIENCES LTD. (SG) | 2017-08-29 | — | — | US | disclosed |
| US-20160347784-A1 | NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES PTE. LTD. (SG) | 2016-12-01 | — | — | US | disclosed |
| US-20120316224-A1 | NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF | ONTORII, INC (US) | 2012-12-13 | — | — | US | disclosed |
| EP-2451461-A1 | NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF | Ontorii, Inc (US) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011005761-A1 | NOVEL NUCLEIC ACID PRODRUGS AND METHODS USE THEREOF | ONTORII, INC (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316224-A1 | NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF | PNP, RNGTT, TYMP | CYP4F2 1517/4885CYP4A11 910/4885SMN1; SMN2 1649/4885 |
| US-20160347784-A1 | NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF | PNP, RNGTT, TYMP | CYP4F2 1517/4885CYP4A11 910/4885SMN1; SMN2 1649/4885 |
| US-10307434-B2 | Nucleic acid prodrugs and methods of use thereof | PNP, RNGTT, NSUN2 | CYP4F2 1525/4885CYP4A11 966/4885SMN1; SMN2 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.